These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30143425)

  • 1. Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonists.
    McGowan DC; Herschke F; Khamlichi MD; Rosauro ML; Benedicto SMP; Pauwels F; Stoops B; Pande V; Scholliers A; Van Schoubroeck B; Mostmans W; Van Dijck K; Thoné T; Horton H; Fanning G; Jonckers THM; Raboisson P
    Bioorg Med Chem Lett; 2018 Oct; 28(19):3216-3221. PubMed ID: 30143425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus.
    McGowan D; Herschke F; Pauwels F; Stoops B; Last S; Pieters S; Scholliers A; Thoné T; Van Schoubroeck B; De Pooter D; Mostmans W; Khamlichi MD; Embrechts W; Dhuyvetter D; Smyej I; Arnoult E; Demin S; Borghys H; Fanning G; Vlach J; Raboisson P
    J Med Chem; 2016 Sep; 59(17):7936-49. PubMed ID: 27513093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B.
    McGowan DC; Herschke F; Pauwels F; Stoops B; Smyej I; Last S; Pieters S; Embrechts W; Khamlichi MD; Thoné T; Van Schoubroeck B; Mostmans W; Wuyts D; Verstappen D; Scholliers A; De Pooter D; Dhuyvetter D; Borghys H; Tuefferd M; Arnoult E; Hong J; Fanning G; Bollekens J; Urmaliya V; Teisman A; Horton H; Jonckers THM; Raboisson P
    J Med Chem; 2017 Jul; 60(14):6137-6151. PubMed ID: 28671847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy.
    Wang Z; Gao Y; He L; Sun S; Xia T; Hu L; Yao L; Wang L; Li D; Shi H; Liao X
    J Med Chem; 2021 Jun; 64(11):7507-7532. PubMed ID: 34048243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists.
    Pieters S; McGowan D; Herschke F; Pauwels F; Stoops B; Last S; Embrechts W; Scholliers A; Mostmans W; Van Dijck K; Van Schoubroeck B; Thoné T; De Pooter D; Fanning G; Rosauro ML; Khamlichi MD; Houpis I; Arnoult E; Jonckers THM; Raboisson P
    Bioorg Med Chem Lett; 2018 Feb; 28(4):711-719. PubMed ID: 29366653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.
    Beesu M; Salyer AC; Brush MJ; Trautman KL; Hill JK; David SA
    J Med Chem; 2017 Mar; 60(5):2084-2098. PubMed ID: 28146629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thermosensitive Gel-Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197.
    Fakhari A; Nugent S; Elvecrog J; Vasilakos J; Corcoran M; Tilahun A; Siebenaler K; Sun J; Subramony JA; Schwarz A
    J Pharm Sci; 2017 Aug; 106(8):2037-2045. PubMed ID: 28456734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Optimization of Selectivity-Tunable Toll-like Receptor 7/8 Agonists as Novel Antibody-Drug Conjugate Payloads.
    Patel AM; Willingham A; Cheng AC; Tomazela D; Bowman E; Kofman E; Zhang F; Bao J; Sanzone JR; Choy JW; Flygare JA; Han JH; Pradhan K; Kieffer M; Chernyak N; Akbari P; Liu P; Mehmood R; Naravula S; Hollingsworth SA; Bhagwat B; Lang SB; Seganish WM
    J Med Chem; 2024 Sep; 67(17):15756-15779. PubMed ID: 39172064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
    Rostamian M; Niknam HM
    Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats.
    Hammerbeck DM; Burleson GR; Schuller CJ; Vasilakos JP; Tomai M; Egging E; Cochran FR; Woulfe S; Miller RL
    Antiviral Res; 2007 Jan; 73(1):1-11. PubMed ID: 16959331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
    Vasilakos JP; Tomai MA
    Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection.
    Tran TD; Pryde DC; Jones P; Adam FM; Benson N; Bish G; Calo F; Ciaramella G; Dixon R; Duckworth J; Fox DN; Hay DA; Hitchin J; Horscroft N; Howard M; Gardner I; Jones HM; Laxton C; Parkinson T; Parsons G; Proctor K; Smith MC; Smith N; Thomas A
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2389-93. PubMed ID: 21419626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants.
    Dowling DJ
    Immunohorizons; 2018 Jul; 2(6):185-197. PubMed ID: 31022686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies.
    Lan T; Dai M; Wang D; Zhu FG; Kandimalla ER; Agrawal S
    J Med Chem; 2009 Nov; 52(21):6871-9. PubMed ID: 19824640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus.
    Embrechts W; Herschke F; Pauwels F; Stoops B; Last S; Pieters S; Pande V; Pille G; Amssoms K; Smyej I; Dhuyvetter D; Scholliers A; Mostmans W; Van Dijck K; Van Schoubroeck B; Thone T; De Pooter D; Fanning G; Jonckers THM; Horton H; Raboisson P; McGowan D
    J Med Chem; 2018 Jul; 61(14):6236-6246. PubMed ID: 29965759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of the anti-tumor effects of imidazoquinoline immune response modifiers by cyclophosphamide.
    Dumitru CD; Antonysamy MA; Tomai MA; Lipson KE
    Cancer Biol Ther; 2010 Jul; 10(2):155-65. PubMed ID: 20519933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
    Hamm S; Rath S; Michel S; Baumgartner R
    J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine.
    Kim H; Griffith TS; Panyam J
    J Pharmacol Exp Ther; 2019 Sep; 370(3):715-724. PubMed ID: 30610006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.
    Bazin HG; Bess LS; Livesay MT; Li Y; Cybulski V; Miller SM; Johnson DA; Evans JT
    Bioorg Med Chem Lett; 2020 Mar; 30(6):126984. PubMed ID: 32001135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.
    Kandimalla ER; Struthers M; Bett AJ; Wisniewski T; Dubey SA; Jiang W; Precopio M; Sun Z; Wang H; Lan T; Agrawal S; Casimiro DR
    Cell Immunol; 2011; 270(2):126-34. PubMed ID: 21570062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.